Erasca Inc
Suletud
11.11 7.97
Ülevaade
Aktsiahinna muutus
24h
Min
10.37
Max
11.43
Sissetulek | -154M -183M |
|---|---|
Aktsiakasum | -0.6 |
Töötajad | 103 |
EBITDA | -5.3M -37M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +96.41% upside |
Järgmine tulemuste avaldamine | 10. aug 2026 |
|---|
Turukapital | -53M 3.2B |
|---|---|
Eelmine avamishind | 3.14 |
Eelmine sulgemishind | 11.11 |
Tehniline skoor
By Trading Central
Kindlus
Bearish Evidence
Erasca Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Erasca Inc Prognoos
Hinnasiht
By TipRanks
96.41% tõus
12 kuu keskmine prognoos
Keskmine 20.27 USD 96.41%
Kõrge 30 USD
Madal 9 USD
Põhineb 11 Wall Streeti analüütiku instrumendi Erasca Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
